APVO 414

Drug Profile

APVO 414

Alternative Names: Anti-PSMA-X-Anti-CD3-ADAPTIR molecule; APVO-414; ES 414; MOR 209 ES 414; MOR-209/ES-414

Latest Information Update: 10 May 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aptevo Therapeutics; Emergent BioSolutions
  • Developer Aptevo Therapeutics; MorphoSys
  • Class Antineoplastics; Bispecific antibodies; Proteins
  • Mechanism of Action CD3 antigen inhibitors; Cytotoxic T lymphocyte modulators; Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 25 Apr 2018 Aptevo therapeutics has patents and pending patents for APVO 414 in USA, Australia, Brazil, Canada, China, Egypt, Europe, Hong Kong, India, Indonesia, Israel, Japan, Malaysia, Mexico, New Zealand, Singapore, South Africa, United Arab Emirates and Vietnam
  • 13 Mar 2018 Phase-I development for Prostate cancer (Hormone refractory, Metastatic disease) is ongoing in USA and Australia (IV)
  • 28 Feb 2018 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Metastatic disease) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top